Nafamostat doses for dialysis blood thinning in ICU
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You are in the ICU and need continuous kidney dialysis (CRRT) for more than 24 hours.
- Normal blood clotting test results (INR ≤ 1.5, fibrinogen ≥ 1.5, APTT ≤ 45 seconds).
- Platelet count of at least 50.
- BMI between 18.5 and 25.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to prevent blood clots during kidney dialysis in people with sepsis-related kidney failure. The goal is to see which method is safer and works better to keep the dialysis filter working properly.
This study looks at two different levels of dosing for continuous dialysis (CRRT) in patients with severe acute kidney injury in the ICU. It aims to find out which dose might be better for recovery.
This study tests whether a specific blood-thinning method using citrate works safely and effectively in critically ill patients whose kidneys have suddenly stopped working and need a special filtering machine. Researchers want to confirm that this approach prevents dangerous blood clots while keeping patients safe.
This trial tests a new medicine called nafamostat to prevent blood clots during continuous dialysis (CRRT), for people who are at high risk of bleeding or can't take heparin.
This pilot study tests whether nafamostat is safe for people on hemodialysis who have a high risk of bleeding. It may help clinicians find safer ways to manage blood clotting medicines during dialysis.
This trial is testing a medicine called nafamostat mesylate for people with sepsis (a severe infection) that causes blood clotting problems and who are receiving hemofiltration (a type of blood filtering). The goal is to see if this medicine helps improve their recovery.
Hear when a new Continuous Renal Replacement Therapy (CRRT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.